Cathie Wood’s ARK sees strong interest in Cerebras stock, trims Tempus AI
ARK ETFs bought 45,729 shares of Cerebras Systems (CBRS) for $5.15M and added to Beam Therapeutics (BEAM) and Joby Aviation (JOBY). They sold 7,625 shares of Tempus AI (TEM) for $584,151, along with smaller reductions in 10X Genomics (TXG), Rubrik (RBRK), CrowdStrike (CRWD), and Cloudflare (NET).
How this was made
The 30-second read
Why it matters
This is a disclosed institutional flow snapshot. It can influence short-term sentiment and positioning, but it is not a fundamental corporate event (no earnings, guidance, product, or regulatory action).
Market read
Traders may use the disclosed ARK flows as a sentiment/positioning input for CBRS and TEM, but the lack of company-specific new fundamentals limits decision value.
What to watch
The article does not state whether these trades change ARK’s target weights, nor does it provide Cerebras or Tempus company-specific news; without that, traders may overfit to fund activity.
Background
The piece summarizes Cathie Wood’s ARK ETF daily trades for Oct 29, 2026, highlighting buys in Cerebras Systems and a trim in Tempus AI.
Ticker impact
ARK bought 45,729 shares of Cerebras Systems across ARKK and ARKW, totaling about $5.15M, signaling fresh fund demand.
Mild upward bias as traders price in continued ARK accumulation, but impact may fade if it is only rebalancing.
The article discloses a specific, sizable ARK purchase and notes continued interest, but it does not provide new company fundamentals or guidance.
ARK trimmed Tempus AI by selling 7,625 shares via ARKK, about $584k, indicating a reduction in exposure.
Slight negative bias as traders react to the disclosed trim, with limited follow-through risk given the small absolute size.
The article provides a concrete sell amount and frames it as strategic rebalancing, but does not cite any new Tempus-specific operational or financial development.
Market effects
Reinforces ARK’s ongoing preference for innovation and tech/biotech exposure, but provides no new sector-level datapoint beyond these specific flow signals.
Primarily US-listed growth/innovation names; no direct cross-region market mechanism described.
Limited global spillover, as the catalyst is fund rebalancing rather than a global macro or supply-chain event.
Counterpoint
ARK daily trade disclosures can reflect routine rebalancing, tax/flow management, or risk controls, so price impact may be short-lived and not predictive of fundamentals.
Key entities
- equityCerebras Systems Inc.
ARK bought 45,729 shares across ARKK and ARKW, about $5.15M.
- equityTempus AI, Inc.
ARK sold 7,625 shares via ARKK, about $584k.
- fundCathie Wood’s ARK ETFs (ARKK, ARKW, ARKG, ARKQ, ARKX)
Vehicles executing the disclosed daily trades.
